אייברנס טבליות 125 מג

Ülke: İsrail

Dil: İbranice

Kaynak: Ministry of Health

Aktif bileşen:

PALBOCICLIB

Mevcut itibaren:

PFIZER PHARMACEUTICALS ISRAEL LTD

ATC kodu:

L01XE33

Farmasötik formu:

טבליות מצופות פילם

Kompozisyon:

PALBOCICLIB 125 MG

Uygulama yolu:

פומי

Reçete türü:

מרשם נדרש

Tarafından üretildi:

PFIZER INC, USA

Terapötik alanı:

PALBOCICLIB

Yetkilendirme tarihi:

2023-06-22

Bilgilendirme broşürü

Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
1
" )
(
-
1986
™
75 "
™
100 "
™
125 "
:
75
,"
100
"
125
"
palbociclib 75 mg, 100 mg or 125 mg
:
6
"
"
.
.
.
,
.
.
.
.
18
.
1 .
?
,
-
HER2
,
:
•
)
(
.
•
(
fulvestrant
)
.
:
,
.
2 .
:
•
)
(
(
6
)
.
: ,
:
•
.
,
•
.
•
.
2
"
,
"
.
•
.
2
."
,
"
.
2
,
"
."
18
.
18
.
. , , ,
.
:
•
:
,
)
(
;
,
,
,
(
)
;
/
,
,
,
(
)
;
(
)
;
(
)
.
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
2
•
:
)
(
;
,
(
)
,
St. John's Wort
(
)
,
,)
(
(
)
;
.
•
,
.
.
•
:
(
,)
,
,
(
)
,
(
,
,)
,)
(
,
(
/
,)
(
,)
(
)
.
.
.
,
•
.
.
-
.
.
-
.
-
.
-
,
.
•
.
.
.
.
3
.
.
.
.
.
,
.
3 .
?
.
.
.
:
•
125
"
21
7
,
28
.
•
,
.
.
•
,
500
"
1
,
15
-
29
.
.
• .
•
.
•
:
.
,
/
.
•
.
,
.
,
,
.
.
.
,
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
3 ! . . , .
4 .
,
.
.
.
:
•
( :)
.
,
.
.
,
,
.
.
•
:
.
:
,
,
,
,
.
•
(
)
:
.
.
,
,
.
(≥ 10%) :
,
(
)
,
,
,
,
,
,
,
,
,
,
,
/
,
,
,
(
)
,
.
:
,
,
,
,
,
. , , , .
"
"
(
www.health.gov.il
)
,
"
:
https://sideeffects.health.gov.il
5 .
?
•
!
/
.
.
•
(
exp. date
)
.
.
•
-
30°C
.
.
•
/
/
.
6 .
:
Microcrystalline cellulose, succinic acid, crospovidone, magnesium
stearate, colloidal silicon dioxide,
hypromellose (E464), titanium dioxide (E171), triacetin, indigo
carmine aluminum lake (E132), iron oxide
red (E172) (75 mg and 125 mg tablets only), iron oxide yellow (E172)
(100 mg tablets only).
:
75
:"
,
,
“Pfizer”
,
-
“PBC 75”
.
100
:"
,
,
“
Pfizer
”
,
-
“
PBC 100
”
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
4
125
:"
,
,
“Pfizer”
,
-
“PBC 125”
.
21
63
.
.
:
,"
'
9
,
46725
. :
75
:"
173-61-36955-99
100
:"
173-62-36956-99
125
:"
173-63-36957-99
,
.
,
.
-
09/2023
.